Bi-Layer Tranexamic Acid Dressings for Trauma Hemostasis

Trauma wound care must often address two linked problems at once: rapid blood loss and microbial contamination. The reference study by Nguyen and colleagues introduces a material strategy that combines antifibrinolytic clot stabilization with nitric oxide-mediated antimicrobial activity and the adhesive properties of propolis. Published in the Journal of Biomedical Materials Research, the study describes a bi-layer TXA–SNAP–propolis dressing designed for early clot formation and antibacterial wound protection. The full report is available through the reference study.

Study Background and Research Question

The authors frame uncontrolled hemorrhage and wound infection as major contributors to poor trauma outcomes. A dressing that only supports coagulation may not sufficiently address bacterial exposure, while an antimicrobial dressing may fail to provide rapid mechanical and biochemical control of bleeding. This motivates a combined design rather than a single-function wound material.

Nitric oxide is central to the paper’s rationale because it participates in several stages of wound repair, including hemostasis, inflammation, cell proliferation, and tissue remodeling. In wound-material research, controlled nitric oxide release has also been associated with antibacterial activity against both common and drug-resistant organisms. Tranexamic Acid, by contrast, is used here as an antifibrinolytic agent: its role is to reduce fibrin breakdown after clot formation, helping preserve the developing hemostatic structure.

The central research question was therefore practical and mechanistic: can a wound-facing layer containing Tranexamic Acid and propolis promote rapid, stable clot formation while a separate layer releases nitric oxide to reduce bacterial survival? The study also asks whether this combination can be fabricated in a form suitable for emergency wound-dressing research rather than treating clotting and infection as unrelated endpoints.

Key Innovation from the Reference Study

The principal innovation is the strategic separation of functions within a bi-layer architecture. The layer placed adjacent to the wound contains TXA suspended on a resinous propolis bed. Propolis contributes natural bioadhesive, antibacterial, and anti-inflammatory characteristics, while TXA is intended to support clot persistence through inhibition of fibrinolysis. The backing layer contains the nitric oxide donor S-nitroso-N-acetylpenicillamine, commonly abbreviated SNAP, embedded in Carbosil, a copolymer based on polycarbonate urethane and silicone.

This arrangement is more than a simple mixture of active ingredients. Positioning the TXA–propolis layer at the wound interface places the clot-stabilizing and adhesive components where blood contact occurs. Locating SNAP in the backing layer creates a separate reservoir for nitric oxide delivery and may help preserve the distinct processing requirements of the two components. The authors evaluated formulations containing 2.5%, 5.0%, and 7.5% propolis by volume, allowing the influence of the resinous matrix to be examined within the same general dressing concept.

The design also clarifies the expected division of labor. TXA is not presented as a substitute for the complete coagulation cascade; rather, it is used to limit fibrin lysis once a clot has begun to form. Propolis provides interfacial adhesion and an additional antimicrobial contribution, while NO is intended to act against wound-associated bacteria. The resulting platform links instant clot-forming behavior with antibacterial wound-dressing research.

Methods and Experimental Design Insights

The study used material fabrication followed by complementary clot and microbiology assessments. First, the researchers constructed the two-layer dressing, incorporating TXA and propolis into the wound-contacting layer and SNAP into the Carbosil-containing base layer. The variable formulation was the propolis content, with three reported levels. This formulation strategy is useful because it changes the bioadhesive and natural-resin component without abandoning the overall TXA–SNAP configuration.

Early clot-associated behavior was examined using a lactate dehydrogenase-based platelet adhesion assay. The assay provided a quantitative approach for comparing platelet-associated material interactions with a control. According to the published study, the relevant early evaluation focused on the first 15 minutes after application, a time window that matches the paper’s emphasis on rapid hemostasis.

Scanning electron microscopy supplied a structural readout that complemented the biochemical assay. Instead of relying only on a signal associated with platelet adhesion, SEM allowed the investigators to inspect the fibrin-rich morphology of the clot and determine whether the dressing surface was associated with a compact fibrin network. This combination of a quantitative assay and direct imaging is important in fibrinolysis research because clot amount and clot organization are related but not identical properties.

Antibacterial performance was tested against Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii. Colony-forming-unit measurements were used to estimate the reduction in viable bacteria after exposure to the dressing system. Testing both a common Gram-positive pathogen and a multidrug-resistant Gram-negative organism strengthened the biological relevance of the antibacterial comparison, although it did not by itself establish performance against the full range of wound contaminants.

Protocol Parameters

• Bi-layer configuration: Use the TXA–propolis component as the wound-facing layer and the SNAP–Carbosil component as the backing layer when reproducing the reference design; this reflects the architecture reported in the reference paper.
• Propolis formulation: Compare the reported 2.5%, 5.0%, and 7.5% volume fractions as formulation variables rather than treating one level as a universal optimum.
• Early clot assessment: Use an LDH-based platelet adhesion assay and evaluate the initial response over a short application window; the study reports its early comparison within 15 minutes.
• Fibrin morphology: Pair assay data with SEM imaging to determine whether an apparent increase in clot-associated signal corresponds to a denser fibrin network.
• Antibacterial endpoint: Quantify viable-cell reduction by colony-forming units for both S. aureus and multidrug-resistant A. baumannii, while maintaining untreated and material-only controls where appropriate.

Core Findings and Why They Matter

The strongest clotting result was observed with the 7.5% T-SP formulation. The authors report increased fibrin activation relative to control during the first 15 minutes of application, based on the LDH-based platelet adhesion assay. SEM provided a corresponding structural observation: the fabricated dressing was associated with a dense fibrin network that supported the interpretation of improved clot stabilization. These findings are consistent with the intended inhibition of fibrinolysis, in which TXA helps prevent premature breakdown of fibrin after the initial clot has formed.

The antibacterial results were also substantial. The dressing produced a reported reduction of 98.9 ± 1% in colony-forming units for S. aureus and 99.4 ± 1% for multidrug-resistant A. baumannii, as documented in the reference study. The paper attributes this activity to the combined contributions of nitric oxide and propolis. Importantly, the data support a dual-function material concept: one dressing can be assessed for both early clot formation and bacterial suppression rather than requiring separate hemostatic and antimicrobial interventions.

For researchers, the significance lies in the alignment of endpoints with trauma-care priorities. A stable fibrin network may be more meaningful than clot initiation alone, while bacterial colony reduction adds a relevant infection-control dimension. At the same time, the study did not report an animal bleeding time reduction endpoint, so the results should not be interpreted as direct evidence of clinical bleeding control. Similarly, the paper used a clot and bacterial model rather than a plasmin-induced neutrophil adherence assay, which would address a different cell-interaction question involving plasmin activity and endothelial adhesion.

Comparison with Existing Internal Articles

The internal article Tranexamic Acid in Fibrinolysis Research is oriented toward plasma assays, cell-adherence models, concentration planning, and fresh-solution handling. Its workflow perspective complements the reference study but covers a different experimental scale: the reference paper embeds TXA within a multifunctional biomaterial, whereas the internal guide emphasizes controlled biochemical and cellular assays for studying antifibrinolytic behavior.

A second relevant resource, Bi-Layer NO–Tranexamic Acid–Propolis Dressings for Rapid Hemostasis, focuses specifically on the same general material concept. The reference paper supplies the primary evidence for the reported fibrin and bacterial outcomes; the internal article can therefore be used as a contextual companion for researchers comparing layer placement, clot-stability measurements, and antibacterial screening. Neither resource removes the need to reproduce the original controls and validate performance in the intended biological model.

Limitations and Transferability

The study is an important proof of concept, but several limitations affect transferability. The reported evidence centers on in vitro or ex vivo assay outputs, microscopy, and bacterial colony counts. These endpoints do not establish how the dressing behaves in a living wound with changing blood flow, inflammatory cells, tissue enzymes, mechanical shear, and variable bacterial burden. In particular, an increase in early platelet-associated signal and a dense fibrin image do not automatically predict reduced hemorrhage in an animal or human injury.

The formulation results also require careful interpretation. Although the 7.5% propolis formulation performed strongly in the reported early assay, the optimal composition may depend on wound exudate, surface chemistry, contact pressure, dressing thickness, and the local balance between adhesion and removability. Propolis is a natural material, so compositional variability and batch-to-batch characterization may be important for reproducible biomaterials research. Future studies should also examine mechanical integrity, controlled SNAP and NO behavior, cytocompatibility, storage stability, dressing removal, and performance under flowing rather than static blood conditions.

Why this cross-domain matters, maturity, and limitations

The study bridges molecular antifibrinolysis, biomaterial engineering, and emergency wound-care modeling. That bridge matters because the same dressing must function at multiple levels: it must contact blood, retain a developing clot, release an antimicrobial mediator, and remain physically attached to tissue. However, the translational maturity is still preclinical. The current findings justify comparative material studies and more physiologically realistic hemostasis models, but they do not support claims of clinical efficacy or replacement of established trauma-care procedures. The most defensible next step is staged validation, beginning with component-isolated controls and progressing to dynamic blood models and appropriately designed in vivo studies.

Research Support Resources

Researchers developing related clot-stability, inhibition of fibrinolysis, or wound-material workflows can use Tranexamic Acid (SKU B1858) as a research reagent for comparable experiments. The product information should be consulted for preparation, solubility, storage, and prompt use of solutions; the material is intended for scientific research only and not for diagnostic or medical use.